Latest Announcements

BSE & NSE corporate filings with AI summaries

BSECompany UpdateMgmt Change3d ago

GLAND PHARMA LIMITED

GLAND PHARMA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left">&nbsp;</td><td class="TTRow_left"><b>&nbsp;Details</b></td></tr> <tr><td ....

Gland Pharma Limited has informed BSE about the appointment of a Chief Investment Officer.

BSECompany UpdateMgmt Change3d ago

GLAND PHARMA LIMITED

GLAND PHARMA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left">&nbsp;</td><td class="TTRow_left"><b>&nbsp;Details</b></td></tr> <tr><td ....

GLAND PHARMA LIMITED has informed BSE about the appointment of a Chief Investment Officer.

BSECompany UpdateMgmt Change3d ago

Gland Pharma Ltd

Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026

Gland Pharma Ltd has appointed Mr. Xiao Le as the Chief Investment Officer of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective November 09, 2026. Mr. Xiao Le has over 15 years of experience in investment and assets management in the medical devices, biopharma, Dx/Tools, and healthcare services sectors.

Read more →📎 1 attachment
NSEAppointmentMgmt Change3d ago

Gland Pharma Limited

Appointment

Gland Pharma Limited has appointed Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le will be responsible for exploring investment opportunities and improving M&A capability for Gland in the US, China, Singapore, and other countries.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults3d ago

Shyam Metalics and Energy Limited

Press Release

Shyam Metalics and Energy Limited has reaffirmed its credit ratings from CRISIL, with a long-term rating of 'CRISIL AA+/Stable' and a short-term rating of 'CRISIL A1+'. The company's bank debt rating has been enhanced to ₹4,500 Crore, and its ₹50 Crore Commercial Paper programme has been reaffirmed at 'CRISIL A1+'.

Read more →📎 1 attachment
NSECopy of Newspaper PublicationResults3d ago

Precision Wires India Limited

Copy of Newspaper Publication

Precision Wires India Limited has informed the Exchange about the publication of unaudited standalone financial results for the quarter and half-year ended September 30, 2026, in newspapers. Sagar Systech Limited has published a corrigendum to its unaudited financial results for the quarter ended September 30, 2026, due to an inadvertent clerical error. The company also announced the sale of immovable properties through e-auction.

Read more →📎 1 attachment
BSECompany Update▲ PositiveExpansion3d ago

Morepen Laboratories Ltd

Please find attached the Press Release

Morepen Laboratories Ltd has announced the launch of its first prescription (Rx) generic product, Desloratadine Tablets USP, in the U.S. market, building on its established API position. The company has also submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP. Morepen intends to pursue additional U.S. prescription generic filings and distribution opportunities.

Read more →📎 1 attachment
NSEPress Release▲ PositiveExpansion3d ago

Morepen Laboratories Limited

Press Release

Morepen Laboratories Limited has announced the launch of its first prescription (Rx) generic product, Desloratadine Tablets USP, in the U.S. market, building on its established API position. The company has also submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP.

Read more →📎 1 attachment
BSEBoard MeetingResults3d ago

Muzali Arts Ltd

Muzali Arts Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results for the Second Quarter and Half Year Ended 30th September, 2026.

Muzali Arts Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/11/2026 to consider and approve the Unaudited Financial Results for the Second Quarter and Half Year Ended 30th September, 2026.

Read more →📎 1 attachment
BSECompany UpdateResults3d ago

United Van Der Horst Ltd

Pursuant to regulation 47 of SEBI (LODR) Regulation, 2015, please find enclosed herewith the extract copies of Newspaper advertisement clippings for Unaudited financial results of the Company for the quarter and half year ended 30th September, 2026

United Van Der Horst Ltd has announced the publication of its unaudited financial results for the quarter and half year ended September 30, 2026, as per Regulation 47 of SEBI (LODR) Regulation, 2015. The results are available on the company's website and the stock exchange's website.

Read more →📎 1 attachment
BSEBoard MeetingResults3d ago

Arvaya Healthcare Ltd

Arvaya Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Pursuant to the provisions of Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that the Meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 13, 2026, to consider and approve, inter-alia, ....

Arvaya Healthcare Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 13/11/2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026.

Read more →📎 1 attachment
NSEAnalysts/Institutional Investor Meet/Con. Call Updates▲ PositiveResults3d ago

Neogen Chemicals Limited

Analysts/Institutional Investor Meet/Con. Call Updates

Neogen Chemicals Limited has informed the Exchange about the Transcript of the Company’s Q2FY27 Earnings Conference Call held on November 2, 2026. The transcript highlights the company's robust all-round performance during the quarter, with consolidated revenue increasing by 42% year-on-year to INR 296 crore and EBITDA improving by 51% year-on-year to INR 45 crore. The company has also approved the expansion of manufacturing facility at Patancheru, Telangana, and successfully completed its maiden Qualified Institutional Placement (QIP) raising INR 600 crore.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults3d ago

Neogen Chemicals Ltd

Earnings Call Transcript - Q2FY2027.

Neogen Chemicals Ltd reported a robust Q2FY27 performance with 42% year-on-year revenue growth to INR 296 crore and 51% year-on-year EBITDA growth to INR 45 crore. The company also announced the expansion of its Organolithium capacity at Patancheru and a successful Qualified Institutional Placement (QIP) raising INR 600 crore.

Read more →📎 1 attachment
← PreviousPage 298 of 15158Next →